Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Operating expenses:        
Research and development $ 742,450 $ 85,000 $ 2,110,846 $ 403,963
General and administrative 1,313,477 1,473,435 3,528,189 5,040,939
Total operating expenses 2,055,927 1,558,435 5,639,035 5,444,902
Operating loss (2,055,927) (1,558,435) (5,639,035) (5,444,902)
Change in fair value of common stock warrants (128,300)   (280,747)  
Warrant financing expense     (192,817)  
Other income (expense), net (283) 1,763,124 (16,954) 1,599,667
Income (loss) before income taxes (2,184,510) 204,689 (6,129,553) (3,845,235)
Income taxes
Net income (loss) (2,184,510) 204,689 (6,129,553) (3,845,235)
Deemed dividends attributable to Series A Preferred Stock     (2,568,132)  
Net income (loss) applicable to common stockholders $ (2,184,510) $ 204,689 $ (8,697,685) $ (3,845,235)
Income (loss) per common share - basic and diluted (in dollars per share) $ (0.18) $ 0.07 $ (1.10) $ (1.44)
Weighted average shares outstanding, basic and diluted (in shares) 12,411,145 3,024,393 7,886,210 2,665,904